Use of aripiprazole in tardive dyskinesia: An open
label study of six cases
World Journal of Biological Psychiatry, 06/10/09
Rajarethinam R et al. - The study supports our hypothesis that clinically stable patients with moderate tardive dyskinesia who are under treatment with other first- or second-generation antipsychotics may benefit from switching to aripiprazole with a reduction of TD symptoms but with out any significant benefit in psychiatric symptoms.
Methods- Six clinically stable patients with schizophrenia or Schizoaffective disorder and a moderate to severe TD participated in this study.
- They were systematically cross-titrated from their current medication to aripiprazole and maintained for 16 weeks.
- The mean extra pyramidal symptom score measured by Abnormal Involuntary Movement Scale (AIMS) improved from a baseline score of 15.8 to final score of 5 (paired t-test; P=0.0009).
- The severity of psychiatric symptoms remained unchanged
No comments:
Post a Comment